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Interleukin (IL)-21 supports induction and expansion of CD8+ T cells, and can also
regulate the differentiation of B cells into antibody-producing plasma cells. We questioned
whether the number of circulating donor-specific IL-21 producing cells (pc) can predict
kidney transplant rejection, and evaluated this in two different patient cohorts. The first
analysis was done on pre-transplantation samples of 35 kidney transplant recipients of
whom 15 patients developed an early acute rejection. The second study concerned
peripheral blood mononuclear cell (PBMC) samples from 46 patients obtained at 6
months after kidney transplantation of whom 13 developed late rejection. Significantly
higher frequencies of donor-specific IL-21 pc were found by Elispot assay in both patients
who developed early and late rejection compared to those without rejection. In addition,
low frequencies of donor-specific IL-21 pc were associated with higher rejection-free
survival. Moreover, low pre-transplant donor-specific IL-21 pc numbers were associated
with the absence of anti-HLA antibodies. Donor-reactive IL-21 was mainly produced
by CD4+ T cells, including CD4+ follicular T helper cells. In conclusion, the number
of donor-specific IL-21 pc is associated with an increased risk of both early and late
rejection, giving it the potential to be a new biomarker in kidney transplantation.
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INTRODUCTION
Interleukin (IL)-21 is a pro-inflammatory cytokine and is produced by several T lymphocytes,
including CD4+, T follicular helper (Tfh) and T-helper 17 (Th17) cells (1, 2). Natural killer T cells
(NKT) cells and CD8+ T cells can also produce IL-21 (3–5).
IL-21 has a diverse effect on a broad range of immune cells. IL-21 drives T and B cell
dependent responses. This pleiotropic cytokine is crucial for T cell-dependent B cell differentiation
of antigen-activated naïve and memory B cells into antibody-producing plasma cells (6–8).
IL-21 increases cytotoxic activity of NK and NKT cells (9), and the cytokine stimulates Th17
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expansion by inducing the expression of the IL-23 receptor
(2). IL-21 can stimulate macrophages that induce CD4+ T
cell proliferation (10). IL-21 also induces proliferation and
expression of effector molecules (IFN-γ, granzyme, perforin)
in CD8+ T cells (11, 12), and facilitates the maturation and
maintenance of memory CD8T cells through STAT3 activation
(13). IL-21 can influence the expression of chemokine receptor
CX3CR1 and integrin α4β7 on CD8+ T cells that results
in the accumulation of these aggressive effector and memory
CD8 cytotoxic T lymphocytes at non-lymphoid tissues (14).
Overproduction of IL-21 occurs in many inflammatory diseases
such as rheumatoid arthritis, psoriasis and SLE (15), and is
reported to be an important pro-inflammatory cytokine in
animal transplant models (16–19).
Studies describing the role of IL-21 after human organ
transplantation are promising. The level of serum IL-21 and
the IL-21-producing capacity of Tfh cells decrease after kidney
transplantation (20, 21), while the number of Tfh cells after
transplantation is the highest in renal transplant recipients with
pre-existent donor-specific antibodies (DSA) (21). Patients with
chronic renal allograft rejection have a characteristic increase in
Tfh cells with a decrease in PD1 expression compared to stable
patients, while the level of serum IL-21 is comparable between
these patient groups (22). In a small cohort of renal allografts, the
presence of Th17 cells producing both IL-17 and IL-21 correlated
with a shorter graft survival (23). We previously described a
positive correlation between the severity of rejection and both
IL-21 and IL-21R mRNA expression after heart transplantation
(24). IL-21 produced by alloantigen antigen activated cells drives
the B cell response (25). We also recently detected IL-21 and Bcl-
6 positive cells in renal transplant biopsies obtained during an
acute rejection (26).
From the described studies it is clear, that IL-21 plays a role
in both cellular and humoral rejection. The Elispot assay enables
quantification of donor-reactive IL-21 producing cells (pc) and
has proven to be a useful monitoring tool due to its sensitive and
accurate detection of rare antigen-specific T-cells and its ability
to visualize single positive cells within a population of peripheral
blood cells (27–29).
The primary aim of the present study was to investigate
whether the number of circulating donor-specific IL-21 pc by
Elispot assay before and 6 months after kidney transplantation
correlates with the development of both cellular and humoral
rejection. In addition, a possible correlation between the number
of donor-reactive IL-21 producing cells and the presence of
anti-HLA antibodies was determined.
MATERIALS AND METHODS
Patients
All patients participated in an investigator-initiated, prospective,
randomized-controlled, parallel group, open label, single center
clinical trial that was performed at the Erasmus MC, University
Medical Center Rotterdam, the Netherlands. The hypothesis,
design and primary outcomes of this trial were published
previously (30). The trial was approved by the institutional
review board of the Erasmus MC (Medical Ethical Review Board
number 2010-080) and the trial was registered in the Dutch
national trial registry (http://www.trialregister.nl/trialreg/admin/
rctview.asp?TC=2226; number NTR2226, registered February 25,
2010) (30). All patients provided written informed consent in
accordance with the declaration of Helsinki. In the present case-
control study, PBMCs from 28 patients were available out of 45
patients who developed rejection. PBMCs from 118 patients were
available without rejection, 54 patients who remained free from
rejection were matched for gender and age with the patients who
did develop rejection.
The first group consisted of 35 patients on the waiting list
for kidney transplantation. PBMCs were sampled just before
transplantation. Fifteen patients developed biopsy-proven acute
rejection, as defined by the Banff classification (31), that was
treated with anti-rejection therapy. Eleven patients experienced
an acute T cell mediated rejection (aTCMR) and four patients
had a mixed-type of rejection [aTCMR + active antibody
mediated rejection (aABMR)]. The second group consisted of
46 renal transplant recipients who were 6 months after kidney
transplantation of which 13 patients developed rejection after 6
months after transplantation. Six of these patients experienced
an aTCMR, one patient an aABMR, one patient chronic active
ABMR (caABMR), four patients a mixed-type of rejection, and
one patient chronic active TCMR (caTCMR). PBMCs were
isolated from all 35 patients prior to transplantation and 46
patients at 6 months after transplantation. Patient characteristics
are described in Table 1.
All patients received induction therapy with basiliximab
(Simulect R©; Novartis Pharma B.V., Arnhem, the
Netherlands) and received maintenance therapy consisting
of tacrolimus (Prograft R©; Astellas Pharma, Leiden, the
Netherlands), mycophenolate mofetil (MMF: Cellcept R©; Roche
Pharmaceuticals, Woerden, the Netherlands) and prednisolone
(30). Prednisolone was tapered from 5mg daily at month 3 after
transplantation to 0mg in 1 month’s time.
Anti-HLA Antibodies
The complement-dependent cytotoxicity cross-match was
negative before transplantation in all patients.
Serum samples from recipients were screened for the presence
of HLA antibodies using the Lifecodes Lifescreen Deluxe
(LMX) kit, according to the manufacturer’s manual (Immucor
Transplant Diagnostics Inc. Stamford, CT, USA). Samples that
were considered positive, scores 6 and 8 i.e., 2,135 MFI, for
either HLA class I (HLA-A, HLA-B, or HLA-C) or HLA class
II (HLA-DR or HLA-DQ) antibodies were further analyzed with
a Luminex Single Antigen assay, using LABscreen HLA class
I and class II antigen beads (One Lambda, Canoga Park, GA,
USA) (32).
Briefly, 4 µl of LABscreen beads and 20 µl of serum were
mixed in a test well, protected from light. Serum samples
were incubated for 30min at room temperature on a rotating
platform (150 rpm), followed by repeated washings with
260 µl wash buffer. Afterwards, each sample was incubated
for 30min with a goat anti-human PE conjugated antibody
(1:100 wash buffer) at room temperature, protected from
light, and subsequently washed 5 times with wash buffer.
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TABLE 1 | Patient characteristics.
Pre-transplantation (n = 35) 6 months post-transplantation (n = 46)
Without rejection
(n = 20)
With rejection
(n = 15)
p-value Without rejection
(n = 33)
With rejection
(n = 13)
p-value
Recipient age (median, range) 57 (37–74) 55 (33–77) 0.73 55 (25–74) 50 (20–68) 0.13
Recipient gender (male) (%) 10 (50%) 11 (73.3%) 0.30 20 (60.6%) 6 (46.0%) 0.51
Caucasian ethnicity (%) 17 (85%) 12 (80%) 1.0 25 (75.5%) 11 (84.6%) 0.70
CAUSE OF ESRD
Diabetes mellitus 3 4 5 2
Hypertension 4 3 9 2
Membranous 2 1 4 1
Nephropathy 1 1 2 1
FSGS 1 1 0 0
Interstitial nephritis 5 3 2 0
Polycystic kidney disease 4 2 11 7
other
Living donor (%) 20 (100%) 12 (80%) 0.07 33 (100%) 13 (100%) 1.0
First transplantation (%) 20 (100%) 11 (73.3%) 0.03 31 (93.9%) 12 (92.3%) 1.0
Total number of HLA mm 3.25 ± 1.45 4.20 ± 1.08 0.04 3.42 ± 1.46 3.38 ± 1.33 0.84
HLA-A mm 1.00 ± 0.73 1.27 ± 0.70 0.29 1.12 ± 0.60 0.92 ± 0.76 0.37
HLA-B mm 1.15 ± 0.59 1.60 ± 0.63 0.03 1.18 ± 0.68 1.15 ± 0.69 0.89
HLA-DR mm 1.10 ± 0.64 1.33 ± 0.62 0.29 1.18 ± 0.64 1.31 ± 0.48 0.59
Anti-HLA antibodies n = 18 n = 13 n = 29 n = 12
Present (%) 1 (5.5%) 7 (53.8%) 0.002 3 (10.3%) 2 (16.6%) 0.62
DSA
Present (%) 0 (0%) 3 (23.1%) 0.01 2 (6.9%) 1 (8.3%) 1.0
ESRD, end stage renal disease; FSGS, focal segmental glomerulosclerosis; mm, mismatches; DSA, donor-specific antibodies.
Samples were measured using a Luminex 100 reader (Luminex
100, Luminex Corporation, ‘s-Hertogenbosch, the Netherlands)
and the baseline normalized values were used. LABscreen
negative control serum (LS-NC, One Lambda) was used as
a negative control.
Peripheral Blood Mononuclear Cells
(PBMCs) Sampling
PBMCs were isolated from heparinised blood by density
gradient centrifugation using Ficoll-Paque (GE Healthcare,
Uppsala, Sweden). The PBMCs were collected from the
interphase, washed twice, and frozen in RPMI-1640 with
glutamax (Life Technologies/Gibco BRL, Paisley, Scotland,
United Kingdom) supplemented with 100 IU/ml penicillin
(Lonza, Basel, Switzerland), 100µg/ml streptomycin (Lonza),
15% heat-inactivated human serum, and 10% dimethyl sulfoxide
(Merck KGaA, Darmstadt, Germany), and stored at −140◦C
until use.
IL-21 Elispot
Polyvinylidene fluoride (PVDF) plates (Millipore, Darmstadt,
Germany) were pre-wetted with 70% ethanol during 1min.
After washing the plate, the wells were coated with 50 µl/well
anti-human IL-21 mAb (U-CyTech Biosciences, Utrecht, the
Netherlands) overnight at 4◦C. After washing the wells with
PBS, the wells were post-coated with 200 µl/well blocking buffer
according to the manufacturer’s protocol.
In brief, triplicates of 3 × 105 patient’s PBMCs were
incubated with 3 × 105 irradiated (40Gy) PBMCs derived from
the donor or 3 × 105 irradiated third-party PBMCs, which
were completely HLA-mismatched with donor and recipient,
in 200 µl culture medium [RPMI-1640 with glutamax (Life
Technologies/Gibco) + 10% heat inactivated FBS (Biowest) +
penicillin + streptomycin (100 IU/ml penicillin, 100 IU/ml
streptomycin; Lonza)]. Unstimulated patient’s PBMC served
a negative control. Cells were incubated in the Elispot plate
for 44 h at 37◦C, 5% CO2, and 95% humidity to allow spot
formation. Thereafter, the wells were firmly shaked-out and
washed with PBS, and 100 µl/well of an appropriately diluted
biotinylated anti-human IL-21 detection antibody (U-CyTech
Biosciences) was added for a period of 2 h. After washing,
the wells were incubated with streptavidin-HRP conjugate
(U-CyTech Biosciences) for 1 h followed by AEC substrate
(U-CyTech Biosciences) until distinct spots emerged within
30min. Color development was stopped by washing extensively
with water. When the Elispot plates were dry, spots were
counted automatically by using a Bioreader 6000 Elispot-reader
(BioSys GmbH, Karben, Germany). In case of response in the
unstimulated PBMCs, this response was subtracted from the
stimulated response.
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Inter- and Intra-assay Variability of IL-21
Elispot Assay
Precision and reproducibility of the donor-specific IL-21 pc
frequency was evaluated by calculating the intra-assay and inter-
assay variability. In case of intra-assay variability, PBMC samples
from 8 transplant patients were tested twice with a 2 weeks
interval, and variability was assessed by calculating the coefficient
of variation (CV), defined by the ratio of the standard deviation
to the mean. CV for Elispot values <10 IL-21 pc/3 × 105 PBMC
were not calculated, because of the possibility of too high SD
values in the low number of IL-21 pc. The median intra-assay
CV was 3.10% (range: 0.00–26.11; Supplementary Table 1). The
inter-assay variability was determined in PBMC samples from 12
patients. Two independent operators determined the number of
donor-specific IL-21 pc. The median inter-assay CV was 8.00%
(range: 1.03–37.94).
Immunostaining of PBMC by Flow
Cytometry
To determine the percentage of different T cell subsets, at least 1
× 106 PBMCs were suspended in isoflow sheath fluid (Beckman
Coulter) and stained in a DuraClone IM T cell tube (Beckman
Coulter, Miami, FL) according to the manufacturer’s protocol.
The T cell tube contained anti-CD45, CD3, CD8, CD4, CD45RA,
and CCR7. Samples were measured by use of the Navios flow-
cytometer (Beckman Coulter).
To determine the Tfh, at least 1 × 106 PBMC were washed
by Fascflow (BD Biosciences, New Jersey, US) and stained with
CD3 BV510 (Biolegend, California, US), CD4 BV421 (Biolegend,
California, US), CXCR5 Alexa Fluor 647 (BD Biosciences, New
Jersey, US), and PD1 APC-Cy7 (Biolegend, California, US) for
30min at room temperature in the dark.
CD4+ and CD8+ Cell Isolation
CD4+ and CD8+ cells were separated from PBMCs by using
the CD4+ T cell and CD8+ T cell isolation kit from Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany. The CD4+ and
CD8+ cells were isolated according to the manufacturer’s
protocol “depletes.” The autoMACS Pro Separator (Miltenyi)
was used to collect the two T cell subsets. The purity of both
populations was >95%.
Mixed Lymphocyte Reaction and
Immunostaining
Patient’s PBMC were stimulated for 3 days at 37◦C, 5% CO2
and 95% humidity with CSFE-labeled, irradiated (40Gy) donor
PBMCs, depleted for CD3+ T cells, in culturemedium. At the end
of day 2 monensin and brefeldin A (GolgiStop and GolgiPlug,
BD Biosciences) were added for 16 h in a concentration of
1:1,500 and 1:1,000, respectively, to allow the measurement
of intracellularly accumulated cytokines in PBMCs. Thereafter,
intracellular IL-21 was measured, and surface marker staining
was used to investigate which subsets produced these cytokines.
Monoclonal antibodies used for surface marker staining and
intracellular cytokine staining were CD3 BV510 (BioLegend),
CD4 BV421 (BioLegend), CD8 PerCP (BD Biosciences), CXCR5
APC (BD Biosciences), PD-1 APC-Cy7 (BioLegend), and IL-21
PE (Biolegend).
Statistical Analysis
Statistical and graphical analysis were performed using SPSS 21.0
(SPSS Inc, Chicago, IL, US) and GraphPad Prism version 5.01
(GraphPad, Inc., La Jolla, CA). Fisher’s exact test was used for
comparisons between patients with and those without rejection.
The Mann-Whitney U-test was used to analyze differences
in phenotype and the number of IL-12 pc between rejectors
and non-rejectors. The Wilcoxon signed rank test was used to
compare the donor and third-party reactive responses. Data is
presented as median and interquartile range. Logistic regression
was performed to assess the odds ratio (OR) and 95% confidence
interval (CI). Receiver operating characteristic (ROC) curve
analysis was used to calculate the cut-off value of number
of donor-specific IL-21 pc. Thereafter, Kaplan-Meier survival
analysis was performed to assess differences in rejection-free
survival between the groups above and below this cut-off value.
A two-sided p-value ≤ 0.05 was considered significant.
RESULTS
Patient Characteristics
The characteristics of patients included are shown in Table 1.
No differences were found regarding age, gender, ethnicity,
cause of end stage renal disease (ESRD), and percentage living
donors in both patient groups. In the pre-transplant cohort,
patients who developed rejection were more often recipients
of a repeat transplant (p = 0.03) and had a higher number
of HLA-B mismatches (p = 0.03). Patients who developed
rejection more frequently had anti-HLA antibodies (p = 0.002)
and DSA (p = 0.01). These differences were not found in the
6-months cohort.
Phenotype of PBMC Samples
No difference was found in the percentage of CD4+ and
CD8+ T cells in PBMC samples between patients with
rejection and without rejection in both patient cohorts
(Supplementary Table 2). Also, the percentage of CD4+ naïve,
central memory, effector memory, and effector memory RA+
(EMRA) cells were comparable between the patients who did
or did not develop rejection (Supplementary Figure 1 and
Supplementary Table 2).
Only in the 6-months samples, the percentage of CD8+ naïve
T cells (CD8+CD45RA+CCR7+) was higher in the patients
who developed late rejection compared to the non-rejection
group [median and interquartile range: 45.28% (25.05–54.61) vs.
23.76% (12.14–38.18), p = 0.02], while the percentage of CD8+
EMRA (CD8+CD45RA+CCR7−) was lower in patients with late
rejection compared to patients without rejection [17.63% (10.72–
42.84) vs. 36.94% (25.28–49.51), p = 0.03]. No difference was
found by logistic regression testing the two covariates CD8+
naïve T cells and EMRA cells: CD8+ naïve T cells, OR = 1.03,
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95% CI = 0.99–1.08, p = 0.16; CD8+ EMRA, OR = 0.97, 95%
CI= 0.92–1.02, p= 0.29.
In addition, the percentage of Tfh cells (CXCR5+PD1+)
within the CD4+ T cell population was not significantly different
between patients who developed rejection and those who did not
[2.17% (1.35–3.20) vs. 2.08% (1.18–3.36), p= 0.81].
Third-Party Reactive IL-21 Producing Cells
In 71 samples (pre-transplantation: n = 25, 6 months: n = 46)
we measured both the number of donor and third-party reactive
IL-21 producing cells. The number of third-party reactive IL-
21 pc was significantly higher than the number of donor-
specific IL-21 pc [median and interquartile range: 35/3 × 105
PBMC (14–74) vs. 23/3 × 105 PBMC (6–58) p = 0.0006]
(Supplementary Figure 2). This probably reflects the fact that
third-party cells are completely HLA mismatched with the
patient and donor, in contrast to the partly HLA matched donor
(mean ± SD: donor 3.38 ± 1.41 vs. third-party 5.11 ± 0.79; p <
0.0001). There was no difference between third-party reactivity
and patients with and without rejection (35/3 × 105 PBMC
[5–72] vs. 33/3× 105 PBMC [15–78], p= 0.67).
Circulating Donor-Reactive IL-21
Producing Cells in Pre-transplant Cohort
Patients who developed an early acute rejection had significantly
higher numbers of pre-transplant donor-reactive IL-21 pc
compared to patients who did not develop rejection [25/3 ×
105 PBMC (16–63) vs. 15/3 × 105 PBMC (4–17), p = 0.02,
Figure 1A]. Seven patients developed an acute TCMR (aTCMR)
grade 1 (n = 6 type 1A, n = 1 type 1B) (31), and 4 patients an
aTCMR grade 2 or 3 (n = 2 type 2A, n = 1 type 2B, n = 3 type
3) (31). Four patients developed a mixed active ABMR (aABMR)
and aTCMR (n = 1 type 1A, n = 2 type 2B, n = 1 type 3). No
difference was found between type of rejection and the number
of donor-reactive IL-21 pc.
ROC analysis showed that at a cut-off value of 18 donor-
specific IL-21 pc per 3 × 105 PBMC, discriminated patients
with an early rejection from patients without a rejection with a
specificity of 80% and a sensitivity of 73% (Figure 2A). Kaplan-
Meier survival analysis demonstrates that patients with low
numbers of donor-specific IL-21 pc (<18/3 × 105 PBMC) have
fewer early rejection episodes compared to those with high
numbers (Figure 2B, p= 0.0005).
The risk of rejection was associated with the number of
transplantations (p = 0.03) and the number of HLA mismatches
(p = 0.04: Table 1). However, an earlier transplant (p = 1.0) and
the number of HLA mismatches (OR = 1.85, 95% CI = 0.98–
3.50, p = 0.06) were not associated with the number of donor-
specific IL-21 pc. The absence of anti-HLA antibodies prior to
transplantation was correlated with the absence of rejection
(Table 1, p = 0.002), and was associated with low numbers
of donor-specific IL-21 pc (OR = 0.05, 95% CI = 0.01–0.50,
p = 0.01). Although a correlation between DSA and rejection
was observed (Table 1, p = 0.01), the absence of DSA was
not associated with low numbers of donor-specific IL-21 pc
(OR= 0.00, p= 0.99).
Circulating Donor-Reactive IL-21
Producing Cells in the 6 Months After
Transplantation Cohort
The number of donor-reactive IL-21 pc at 6 months after
transplantation was significantly higher in patients who
developed rejection compared to those who did not develop
rejection [Figure 1B, 52/3 × 105 PBMC (23–106) vs. 23/3 × 105
PBMC (5–48) p = 0.01]. Six patients developed aTCMR (n = 2
type 1A, n = 2 type 1B, n = 2 type 3), one patient developed
chronic active TCMR (caTCMR), one patient developed aABMR
and one chronic, active ABMR (caABMR), and 4 patients
developed a combined aABMR and aTCMR (n = 1 type 1A,
n = 2 type 1B, n = 1 2A). No association between the number
of donor-reactive IL-21 producing cells and the type of rejection
was found.
ROC curve analysis suggested that the frequency of donor-
reactive IL-21 pc can distinguish rejection from non-rejection
with 62/3 × 105 PBMC as a cut-off value with a specificity
of 88% and sensitivity of 54% (Figure 2C). Patients with <62
FIGURE 1 | Number of post-transplant donor-specific IL-21 producing PBMC in patients who will or will not develop rejection in pre-transplant cohort (A: n = 20
without rejection, n = 15 with rejection) and 6 months post-transplant cohort (B: n = 33 without rejection, n = 13 with rejection).
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FIGURE 2 | Receiver operating characteristic (ROC) analysis was performed to define the cut-off number of donor-specific IL-21 producing cells (pc) (A: PBMC
samples taken from patients prior to transplantation; C: PBMC samples taken from patient at 6 months after transplantation), and discriminated between patients with
and without rejection. A cut-off of 18 spots per 300.000 PBMCs was determined with a specificity of 80% and a sensitivity of 73% in the pre-transplant cohort (A),
and a cut-off of 62 spots per 300.000 PBMCs was determined with a specificity of 88% and a sensitivity of 54% in the 6 months post-transplant cohort (C).
Thereafter, the percentage of patients with high and low numbers (cut-off values) of IL-21 pc free from rejection were determined in the pre-transplant (B) and
post-transplant cohort (D). AUC, area under the curve.
donor-specific IL-21 pc/3× 105 PBMC had a significantly higher
rejection-free survival rate than patients with higher numbers
(Figure 2D, p= 0.0005).
IL-21 Producing Cells in CD4+, CD8+ T
Cells, and Tfh Cells
We isolated CD4+ T cells and CD8+ T cells to investigate the
contribution of these T cell subsets to the IL-21 response. We
investigated donor-specific IL-21 reactivity in PBMC, CD4+, and
CD8+ T cells from 4 patients. In all combinations 3 × 105
patient’s cells were stimulated with 3× 105 irradiated donor cells.
The response from the PBMC was set as 100%, and compared
with the CD4+ and CD8+ T cell reactivity. Figure 3 depicts that
donor-specific IL-21 was mainly derived from the CD4+ T cells,
while contribution of CD8+ T cells to IL-21 production was
only minor.
A mixed lymphocyte reaction (MLR) was performed to
determine the percentage IL-21 positive cells amongst the
CD4+, CD8+ and Tfh cells by flow-cytometry. Figure 4 shows
a representative example (Figure 4A). Only a few cells from the
CD8+ T cells (1.97%) were able to produce IL-21 (Figure 4B),
while 15.87% of the CD4+ T cells did produce IL-21 (Figure 4C).
This was comparable with the Elispot results of Figure 3.
1.18% of the CD3+CD8+ cells expressed CXCR5, from
the CD3+CD8+CXCR5+ cells 35.65% also expressed PD1
(Figure 4D). The percentage of CD3+CD8+CXCR5+PD1+ cells
was too low to be analyzed for IL-21. CD3+CD4+ cells contained
15.13% CXCR5+ cells, 36.75% of these cells were Tfh cells
(CD3+CD4+CXCR5+PD1+) (Figure 4E). From these CD4+ Tfh
cells 31.22% contained donor-reactive IL-21 pc (Figure 4F).
We performed this MLR in 5 transplant recipients
(Figure 4G). Again, a higher percentage of donor-reactive
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FIGURE 3 | The donor-specific IL-21 producing cell frequency determined in
PBMC, CD4+ and CD8+ T cells in PBMCs of four transplant recipients. The
IL-21 response in PBMC was defined as 100%. Mean with SEM is presented.
IL-21 positive cells was found among the CD4+ T cells (median,
interquartile range; 7.72% [5.88–10.56]) compared to the CD8+
T cells (1.16% [0.42–1.90]), and 27.11% (12.16–35.06) of the Tfh
cells were able to produce IL-21.
DISCUSSION
IL-21 is an immunomodulatory cytokine with pleiotropic
functions that regulates both the innate and adaptive immune
reaction. This cytokine can activate cytotoxic T lymphocytes
(CTLs), and can induce immunoglobulin production via
stimulation of B cells that transform into plasma producing
cells (6–8, 11–14).
The present study demonstrates that the pre-transplant
number of donor-specific IL-21 pc could predict early acute
rejection after renal transplantation. In addition, the frequency of
donor-reactive IL-21 pc 6 months after transplantation predicted
late rejection (>6months after transplantation). Importantly, the
number of third-party reactive IL-21 pc did not correlate with
rejection. High numbers of donor-reactive IL-21 pc were found
in patients who developed both aTCMR and/or aABMR, and no
difference was found in the number of donor-specific IL-21 pc
between patients with different types of rejection. This suggests
that IL-21 is involved in both cellular and humoral allogeneic
responses. This could be explained by the broad pleiotropic
actions of IL-21. This cytokine modulates the function of both
effector cytotoxic CD8T cells and the development of Th17 cells
that can induce cellular rejection (11, 12, 33, 34), and it is also
a key factor for the differentiation of B cells into plasma cells
that produce DSA resulting in humoral rejection (8). In both
the pre-transplant and 6-months post-transplant group, patients
with low donor-specific IL-21 pc frequencies had a significantly
increased rejection-free survival rate compared to those with
high frequencies.
The correlation of donor-specific IL-21 pc and rejection could
not be explained by the percentage of Tfh cells (CXCR5+PD1+
T cells) within the PBMC population, as the percentage of
Tfh cells was comparable between patients with and without
rejection. In previous studies a correlation with Tfh cells and
infection was found (35–37), but each research group uses
different phenotypic markers to define these circulating Tfh [e.g.,
CD4+CXCR5+ T cells (35), CD4+ICOS+CXCR3+CXCR5+
(36), CD4+CXCR5+CXCR3+PD1low/high (37)]. All these cells
resemble Tfh cells in peripheral blood. However, different patient
groups and different phenotypic markers of these Tfh cells may
lead to difficulties in comparing the findings in these studies.
This latter has been recognized by others. Schmitt et al. showed
a general strategy to define Tfh cells based in cell surface
profiles (38). Probably, CXCR5+PD1+ circulating Tfh cells are
not specifically directed to the allograft. Rather, these cells could
have a general effect on immune reactivity including anti-viral
responses and autoimmune reactions.
The donor-reactive IL-21 response was mainly produced by
CD4+ cells, because the CD4+ T cells contained significantly
higher numbers of donor-specific IL-21 pc than the CD8+ T cell
population both determined by Elispot assay and flow-cytometry.
A main producer (27%) of donor-reactive IL-21 are Tfh cells.
Therefore, we consider that donor-reactive IL-21 producing cells
do not only derive from Tfh cells, but probably activated CD4T
cells and Th17 cells will produce the main part of IL-21 in the
Elispot assay (33).
IL-21 can induce the differentiation of CD8+ T cells into
effector CD8+ T cells by increasing granzyme B, perforin, IFN-
γ, the chemokine CXCR1, and the integrin α4β7 on effector
CD8+ cells (11–14). IL-21 has antitumor effects. Recombinant
IL-21 given to melanoma and MethA fibrosarcoma mice models
delayed tumor progression via increased number of anti-tumor
CTLs (39, 40). Remarkably, perforin, and not IFN-γ or other Th1
or Th2 cytokines, is required for the IL-21 antitumor response
(39). These data suggest that IL-21 has a unique ability to
promote the ability of CD8+ T cells to become potent effector
CTLs. Therefore, we postulate that IL-21 activates allo-reactive
CD8+ CTLs that migrate to the allograft resulting in an aTCMR.
The presence of anti-HLA antibodies is a marker for sensitized
kidney transplant recipients. These sensitized recipients had
higher frequency of donor-specific IL-21 pc. Because interruption
of signaling by an IL-21 receptor antagonist abolished the ability
to stimulate B cell development and antibody production (25),
the high numbers of IL-21 pc present prior to transplantation
might be related to the presence of anti-HLA antibodies.
High numbers of IL-21 pc might promote anti-HLA antibody
formation by providing help to alloantigen activated B cells and
an inflammatory response in graft, that results in an aABMR.
Unfortunately, not enough aABMR samples were available to
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FIGURE 4 | A typical example is depicted for intracellular IL-21 production after stimulation of patient’s PBMCs with irradiated donor PBMCs depleted for CD3 (A).
The proportion of IL-21 producing cells was determined after 3 days within the CD8+ (B) and CD4+ T cells (C). Tfh cells (CXCR5+PD1+) were determined within the
CD8+ (D) and CD4+ (E) T cell population. The percentage of CD8+ Tfh cells was too low to be analyzed for IL-21. Within the CD4+ Tfh cells 31.22% produced IL-21
(F). The proportion of IL-21 producing cells was determined in PBMC samples from 5 kidney transplant recipients (G). The percentage donor-reactive IL-21 was
determined in CD4+ and CD8+ T cells, and Tfh cells (CD4+CXCR5+PD1+). IgG1 isotypes are presented of each T cell subpopulations.
confirm this hypothesis. Therefore, further studies are necessary
to elucidate the function of IL-21 underlying this process of
aTCMR and aABMR.
The importance of IL-21 has already been demonstrated
in preclinical studies in autoimmune disease (15, 41, 42).
Patients with rheumatoid arthritis, SLE, type 1 diabetes mellitus,
and Crohn’s disease can participate in phase 1 and 2 clinical
trials with anti-IL-21 monoclonal antibody therapy (43). Anti-
IL-21 monoclonal antibody therapy could be an promising
prophylactic treatment to prevent both aTCMR and aABMR.
The early treatment of anti-IL-21 monoclonal antibodies could
prevent the invasion of aggressive CTLs into the graft and the
development of DSA.
In summary, donor-reactive IL-21 pc determined by Elispot
assay could have the potential to predict allograft rejection. The
present study has some limitations. Because of the small numbers
of rejection samples, differences between aTCMR and aABMR
could not be found. A prospective validation study and an
external multicentre validation of the number of donor-specific
IL-21 pc predicting rejection is advisable. Probably, adding more
donor-reactive cytokine producing cells to the study cohort could
more clearly discriminate aTCMR from aABMR.
In conclusion, the number of donor-specific IL-21 pc can
predict rejection at different phases after kidney transplantation.
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